Pharmaceutical News

RSS

Evosep expanding capabilities with new headquarters to support rising needs in pharma and biotech for proteomics

...

From Evosep 28 Oct 2024

Expanded access to weight-loss drugs could save thousands of lives

Researchers explore the potential benefits of expanding access to novel weight loss drugs to enhance survival rates in overweight and obese individuals.

28 Oct 2024

Bioactive peptides from Chlorella vulgaris for therapeutic applications

Chlorella vulgaris is a green, photosynthetic microalga in the phylum Chlorophyta. The goal of our study was to perform a bioinformatics analysis of Photosystem I P700 chlorophyll a apoprotein A2, one of its photosynthesis-related proteins, and to hunt for potent bioactive peptides.

27 Oct 2024

Tenofovir amibufenamide does not alter lipid levels in patients with chronic hepatitis B

The effect of tenofovir amibufenamide (TMF) on blood lipid profiles in patients with chronic hepatitis B (CHB) remains unclear. This study aimed to explore whether TMF affects blood lipids during 48 weeks in patients with CHB.

26 Oct 2024

New trial shows felzartamab reduces proteinuria in IgA nephropathy patients

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface.

26 Oct 2024

New analysis confirms canagliflozin's cardiovascular and kidney benefits in older adults

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients' age.

26 Oct 2024

Study: GLP-1RA not associated with acute kidney injury risk during anti-cancer treatments

Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear.

26 Oct 2024

Diabetes drug semaglutide proves beneficial for patients with chronic kidney damage and obesity

The diabetes drug semaglutide, also known as Ozempic, has a positive effect for patients with chronic kidney damage and obesity. They

26 Oct 2024

Ipsen's elafibranor recommended for use in patients with rare liver disease

Ipsen announced today that the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. This makes elafibranor the first medicine for PBC approved for use on the NHS in nearly a decade.

26 Oct 2024

MHRA greenlights donanemab for early stage Alzheimer’s disease

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the medicine donanemab (Kisunla) for use in the early stages of Alzheimer’s disease, following a thorough review of the benefits and risks.

26 Oct 2024

Surge in GLP-1 drug use for obesity coincides with drop in bariatric surgery

Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter.

26 Oct 2024

Taurine supplementation linked to reduced atherosclerotic plaque development

Previous studies suggest that taurine supplementation may attenuate atherosclerosis by reducing lipid levels. However, energy drinks containing taurine have been shown to increase blood pressure, a key risk factor for atherosclerosis. Thus, the role of taurine in atherosclerosis remains controversial.

26 Oct 2024

Endophyte fermentation boosts isofraxidin levels in Sarcandra glabra

Isofraxidin, an important coumarin compound found in the medicinal plant Sarcandra glabra, is reported to have anti-inflammatory activity.

25 Oct 2024

Study reveals misuse of scientific evidence by opioid makers

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that makers and marketers of prescription opioid painkillers misused scientific evidence to advance five common and inaccurate claims about the safety and effectiveness of prescription opioids - including that they were not addictive.

25 Oct 2024

Semaglutide may reduce Alzheimer's risk in diabetics

Researchers use real-world data in the United States to evaluate the protective role of semaglutide against Alzherimer’s disease.

25 Oct 2024

Antibiotic for liver disease linked to emergence of antimicrobial resistant superbug

An international team of researchers has found that an antibiotic commonly prescribed for patients with liver disease, called rifaximin, has led to the global emergence of an almost untreatable form of the antimicrobial resistant superbug vancomycin-resistant enterococcus faecium (VRE), which frequently causes serious infections in hospitalized patients.

24 Oct 2024

Semaglutide may lower Alzheimer's risk in type 2 diabetes patients

Researchers at the Case Western Reserve School of Medicine have found that, when compared to seven other anti-diabetic drugs, semaglutide, a popular diabetes and weight-loss drug, may lower the risk of Alzheimer's disease in people with type 2 diabetes (T2D).

24 Oct 2024

HER2-postive breast cancer drugs show promise for bile duct cancer treatment

Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

23 Oct 2024

New chemical language model can predict dual-target drug candidates

Researchers from the University of Bonn have trained an AI process to predict potential active ingredients with special properties.

23 Oct 2024

Advancements in antibody-drug conjugates transform cancer therapy

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of cytotoxic drugs.

22 Oct 2024